Nanotargeted agents: an emerging therapeutic strategy for breast cancer

Nanomedicine (Lond). 2019 Jul;14(13):1771-1786. doi: 10.2217/nnm-2018-0481. Epub 2019 Jul 12.

Abstract

Breast cancer is the most common female cancer worldwide and represents 12% of all cancer cases. Improvements in survival rates are largely attributed to improved screening and diagnosis. Conventional chemotherapy remains an important treatment option but it is beset with poor cell selectivity, serious side effects and resistance. Nanoparticle drug delivery systems bring promising opportunities to breast cancer treatment. They may improve chemotherapy by targeting drugs to tumors, generating high drug concentrations at tumors providing slow release of the drug, increased drug stability and concomitant reductions in side effects. The nanotechnology-based drug delivery approaches and the current research and application status of nano-targeted agents for breast cancer are discussed in this review to provide a basis for further study on targeted drug delivery systems.

Keywords: active targeting; breast cancer; nano-targeted agents; passive targeting; physical and chemical targeting.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Drug Carriers / chemistry*
  • Drug Carriers / metabolism
  • Drug Delivery Systems / methods*
  • Female
  • Humans
  • Nanomedicine / methods
  • Nanoparticles / chemistry*
  • Nanoparticles / metabolism
  • Nanotechnology / methods

Substances

  • Antineoplastic Agents
  • Drug Carriers